BioLineRx Ltd. (BLRX) is a leading clinical-stage biopharmaceutical company dedicated to identifying, developing and commercializing promising therapeutics for unmet medical needs. The company’s focus is primarily on oncology and immunology, with an innovative in-house pipeline and strategic collaborations designed to increase the likelihood of bringing new treatments to market.
Established in 2003, BioLineRx Ltd. is headquartered in Jerusalem, Israel, and has a strategic partnership with GENESIS Pharma S.A. for the distribution of novel therapies in Greece, Cyprus, Romania, and Slovenia. BLRX operates by acquiring preclinical or early clinical therapeutic assets, usually with an initial focus on unmet medical needs and a clear-cut marketing strategy.
Over the years, BioLineRx Ltd. has been devoted to advancing a variety of compound programs in development into novel standalone drugs. One of their lead clinical programs includes Motixafortide (BL-8040), a CXCR4 antagonist that has shown promising results in several oncology treatments, including stem cell mobilization, acute myeloid leukemia, and solid tumors. The candidate is undergoing multiple phase 2 and phase 3 trials at various stages worldwide.
Beyond its in-house pipeline, BioLineRx is also committed to establishing strategic partnerships and collaborations with pharmaceutical companies worldwide, broadening the potential of its therapeutic candidates. By utilizing this synergistic business model, BLRX aims to expedite the clinical development process and achieve market reach and penetration more effectively.
Despite the economically challenging times, BioLineRx continues to sustain its commitment to research and development endeavors. The company believes its development model, which involves de-risking assets before moving through to costly later-stage trials, will continue to prove beneficial in the long run.
BioLineRx’s mission is to increase the life expectancy and quality of life for cancer patients worldwide by leveraging its deep scientific understanding to develop innovative and effective therapies. To that end, the company and its management team are dedicated to realizing the full potential of cutting-edge biotechnological research and turning it into solutions for patients in need.
Financially, the company trades on the Nasdaq and the Tel Aviv Stock Exchange under the ticker BLRX. In recent years, it has seen an increase in revenues and an augmentation in institutional funding. However, like all biotech firms, BLRX is still subject to the inherent risks and uncertainties associated with drug discovery and development.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
BioLineRx Ltd. (NASDAQ:BLRX) has filed a Form F-1 registration statement with the SEC to allow for the resale of up to 2,023,382 American Depositary Shares (ADSs) by a selling shareholder. These ADSs are tied to warrants issued during a private placement in August 2026. BioLineRx will not receive proceeds from this ADS resale, but may gain funds from any cash exercises of the warrants.
BioLineRx Ltd. (BLRX) reported its Q2 2026 financial results, with basic and diluted EPS of $0.00, meeting estimates. The company generated revenue of $294,000, which is a decrease from the prior year, and recorded a net loss of $4.3 million. BioLineRx maintained cash and cash equivalents plus short-term deposits of $13.1 million, providing liquidity for its ongoing clinical trials and product development.
BioLineRx Ltd. reported Q2 2026 financial results, including license revenues of $294,000 and a net loss of $4.3 million. The company's GLIX1 development program, in a joint venture with Hemispherian, is advancing with the enrollment of the second cohort in its Phase I/IIa trial for glioblastoma, and new preclinical data suggests a synergistic effect when GLIX1 is combined with a PARP inhibitor. BioLineRx also executed a $3.75 million capital raise to support its development pipeline and expects to fully repay its term loan by the end of 2027.